Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent

IL-31 Inhibitor On File In US And EU

Galderma presented long-term extension data from its Phase III trials in atopic dermatitis and prurigo nodularis at AAD for its first-ever therapeutic biologic, taking on a formidable competitor.

Different light bulb glowing in a line
Galderma is set to position nemolizumab as a unique option • Source: Shutterstock

Galderma S.A. will launch its first-ever therapeutic biologic in 2024, assuming US Food and Drug Administration approval is granted later this year, and presented long-term data at the American Academy of Dermatology (AAD) meeting in San Diego that it believes will make the case for preferential use of its IL-31 receptor alpha inhibitor nemolizumab in prurigo nodularis (PN) and in certain Dupixent (dupilumab)-treated and -naïve patients with atopic dermatitis (AD).

Key Takeaways
  • Galderma reported positive longer-term data for its IL-31 inhibitor nemolizumab in prurigo nodularis (PN) and atopic dermatitis (AD) that it believes differentiate the drug, including versus market leader Dupixent (dupilumab).

The private Swiss company, which announced on 6 March that it plans to go public on the SIX Swiss Exchange,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

More from R&D

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

 

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

Decentralized Trials Enroll Larger, More Diverse Patient Populations

 

A new study by Tufts CSDD performed a deep dive into use of decentralized clinical trial techniques, but one of the study’s authors said DCTs have been dialed back.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.